Search results
Showing 31 to 39 of 39 results for alzheimer's disease
IMI and H2020 Grant funded projects with NICE
The benefits from donanemab (also called Kisunla and made by Eli Lilly) and lecanemab (also called Leqembi and made by Eisai) - remain too small to justify the additional cost to the NHS, one of our independent committees has concluded following consultation.
NICE's past research and projects
NICE priority methodological research areas.
Second consultation launched on NHS funding for Alzheimer's treatments
Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab.
Working at the forefront of neurodegenerative disease research
Claire Hawksworth reveals NICE’s role in a global partnership to better understand neurodegenerative conditions and speed up delivery of innovative treatments.
Benefits of new Alzheimer's treatment lecanemab are too small to justify the cost to the NHS
Our draft recommendation follows analysis of clinical trial evidence and reviewing the benefits of slowing disease progression, with the cost of treatment.
NICE’s methods and processes for evaluating new treatments for use in the NHS are appropriate for the new class of Alzheimer’s drugs but key issues need to be considered, a new report has found.
New Alzheimer's treatment donanemab does not currently demonstrate value for the NHS says NICE
More evidence is needed on the clinical and cost-effectiveness of donanemab, a new treatment for mild Alzheimer’s disease.